SG Americas Securities LLC Buys 12,544 Shares of Bio-Rad Laboratories, Inc. $BIO

Key Points

• SG Americas Securities LLC boosted its Bio‑Rad holding by 195.6% in Q4, buying 12,544 shares to own 18,958 shares (about 0.07% of the company) valued at roughly $5.74 million.
• Bio‑Rad missed the quarter on EPS ($2.51 vs. $2.57 est.) and revenue ($693.2M vs. $694.6M) despite 3.9% YoY revenue growth; shares opened at $278.54 (52‑week range $211.43–$343.12), market cap ~$7.52B, P/E ~9.98, and analysts have a consensus Hold with a $358.50 price target.

SG Americas Securities LLC lifted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 195.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,958 shares of the medical research company's stock after purchasing an additional 12,544 shares during the period. SG Americas Securities LLC owned 0.07% of Bio-Rad Laboratories worth $5,744,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Quent Capital LLC purchased a new stake in Bio-Rad Laboratories in the third quarter worth $25,000. Farther Finance Advisors LLC lifted its position in shares of Bio-Rad Laboratories by 52.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company's stock valued at $29,000 after buying an additional 36 shares during the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Bio-Rad Laboratories by 115.2% during the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares during the last quarter. CWM LLC grew its stake in shares of Bio-Rad Laboratories by 82.0% during the 3rd quarter. CWM LLC now owns 202 shares of the medical research company's stock worth $57,000 after acquiring an additional 91 shares during the period. Finally, UMB Bank n.a. grew its stake in shares of Bio-Rad Laboratories by 24.0% during the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company's stock worth $58,000 after acquiring an additional 40 shares during the period. Hedge funds and other institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Up 3.0%

Shares of NYSE BIO opened at $278.54 on Wednesday. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $343.12. The business has a 50-day simple moving average of $279.88 and a two-hundred day simple moving average of $298.57. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16. The company has a market cap of $7.52 billion, a P/E ratio of 9.98 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing analysts' consensus estimates of $2.57 by ($0.06). Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The company had revenue of $693.20 million for the quarter, compared to analysts' expectations of $694.64 million. During the same period in the previous year, the firm earned $2.90 EPS. The firm's quarterly revenue was up 3.9% compared to the same quarter last year. Research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on BIO shares. Weiss Ratings restated a "sell (d-)" rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, February 14th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bio-Rad Laboratories presently has an average rating of "Hold" and a consensus price target of $358.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.